Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease ...Middle East

– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks – – Data highlight durable response to treatment. At the 0.3 mg/kg dose, 60% of patients who responded to axatilimab were still responding at...

Hence then, the article about syndax and incyte announce positive topline results from the pivotal agave 201 trial of axatilimab in chronic graft versus host disease was published today ( Monday 24/07/2023 - 02:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease )

Also on site :

• Art’s Angle: Three-Ring Circus
• ‘The Comeback’ took on Hollywood long before ‘The Studio.’ Now, Valerie Cherish will have her curtain call
• Virat Kohli BRUTALLY trolls media on India-London chartered flight rumours